Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: PF-04691502|DRUG: Exemestane|DRUG: Exemestane
Sponsor: Pfizer